Li, Mengke http://orcid.org/0009-0006-3602-4129
Tang, Hongzhi http://orcid.org/0000-0002-7743-0186
Qing, Rui http://orcid.org/0000-0002-7952-2295
Wang, Yanze
Liu, Jiongqin
Wang, Rui
Lyu, Shan
Ma, Lina
Xu, Ping http://orcid.org/0000-0002-4418-9680
Zhang, Shuguang http://orcid.org/0000-0002-3856-3752
Tao, Fei http://orcid.org/0000-0002-5997-8770
Funding for this research was provided by:
National Natural Science Foundation of China (32170105)
Article History
Received: 11 August 2023
Accepted: 3 May 2024
First Online: 10 June 2024
Competing interests
: S.Z. is a member of board director of 511 Therapeutics that generates therapeutic monoclonal antibodies against solute carrier transporters. He is also a scientific advisor for OH2 Laboratories that works on generating therapeutic monoclonal antibodies against GPCRs. However, this study does not involve in GPCRs and solute carrier transporters. OH2 Laboratories licensed the QTY code technology from MIT. However, this article does not study GPCRs. S.Z. is the inventor of the QTY code and has a minor equity of OH2 Laboratories and majority equity in 511 Therapeutics shares that works on solute carrier transporters. S.Z. is also a scientific advisor for 3DMatrix Co Ltd, that commercializes self-assembling peptide hydrogels for surgical and accelerated wound-healing applications. MIT filed several patent applications for the QTY code for GPCRs and glucose transporters. The current study does not involve in GPCRs and glucose transporters. S.Z. is a co-founder and board director of Molecular Frontiers Foundation that encourages young people to ask good questions about science and nature and also organizes Molecular Frontiers Symposia around the world. There is no compensation for the activities. The remaining authors declare no competing interests.